サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757725

脂肪肝治療の世界市場

Fatty Liver Treatment

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.70円
脂肪肝治療の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脂肪肝治療の世界市場は2030年までに231億米ドルに達する見込み

2024年に187億米ドルと推定される脂肪肝治療の世界市場は、2024～2030年の分析期間においてCAGR 3.6%で成長し、2030年には231億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるチアゾリジンジオンは、CAGR 3.0%を記録し、分析期間終了時には66億米ドルに達すると予測されます。ビタミンEセグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は51億米ドルと推定される一方、中国はCAGR 6.5％で成長すると予測される

米国の脂肪肝治療市場は、2024年には51億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに46億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と2.7％と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の脂肪肝治療市場- 主要動向と促進要因まとめ

脂肪性肝疾患が世界の健康問題になりつつあり、標的治療が必要となっているのはなぜか？

非アルコール性脂肪性肝疾患（NAFLD）とアルコール性脂肪性肝疾患（AFLD）の両方を含む脂肪性肝疾患は、その有病率の上昇、代謝障害との密接な関連、および脂肪性肝炎、線維症、肝硬変、肝細胞がんなどのより重篤な肝疾患に進行する可能性のために、世界的に重大な公衆衛生問題として浮上しています。現代人の座りがちなライフスタイル、食生活の乱れ、肥満率の上昇、2型糖尿病の罹患率の増加などが、脂肪肝、特にNAFLDの憂慮すべき増加の原因となっており、現在では世界人口の25％が罹患しています。NAFLDは世界人口の25％が罹患しています。その有病率にもかかわらず、脂肪肝疾患は初期段階では症状がないため診断されないことが多く、介入せずに進行することが多いです。その結果、生活習慣の改善プログラムや薬理学的介入から重症例では外科的解決に至るまで、効果的な治療法の開発と実施が急務となっています。さらに、脂肪性肝疾患と心血管合併症との間に潜在的な関連があることから、その医学的意義はさらに高まっており、その治療は肝臓の健康にとって不可欠であるだけでなく、より広範な全身的リスクを軽減するためにも重要です。臨床医と患者双方の認識が向上するにつれ、早期診断と個々の患者に合わせた治療戦略は、疾患の進行を遅らせ、慢性肝疾患に伴う長期的なヘルスケア負担を軽減する上で極めて重要になってきています。

治療イノベーションは脂肪肝疾患の管理をどのように変革しているか？

医学研究と医薬品開発の進歩は、より効果的な疾患管理と長期的な転帰への希望をもたらし、肝疾患の状況を急速に変えつつあります。伝統的に、食生活の改善、運動量の増加、減量などの生活習慣の改善は、脂肪肝疾患に対する防御の第一線として機能してきました。しかし，患者のアドヒアランスの限界と一貫した治療成績の欠如から，薬理学的解決策の追求が加速しています。現在，脂質代謝，炎症，線維症，インスリン抵抗性の主要な機序を標的とするいくつかの薬剤候補が臨床試験中であり，FXR作動薬，PPAR作動薬，GLP-1受容体作動薬などが含まれます。ピオグリタゾンやビタミンEのような薬剤は、特定の患者サブグループにおいて緩やかな成功を示しているが、オベチコール酸やレスメチロムのような新しい薬剤は、NASH（非アルコール性脂肪性肝炎）患者の肝脂肪量と線維症の減少において有望な結果を示しています。単剤治療に加えて、複数の病態経路に同時に対処する併用療法が、より効果的な治療法として注目されています。また、FibroScan、MRI-PDFF、血清バイオマーカーなどの非侵襲的診断ツールの統合により、治療モニタリングが強化され、個別化された治療計画が可能になりつつあります。さらに、デジタルヘルスツールやモバイルヘルスアプリは、行動追跡や遠隔医療サポートを通じて、患者がライフスタイルの変化を維持するのに役立っています。こうした治療イノベーションは、臨床転帰を改善するだけでなく、脂肪肝治療をより利用しやすく、エビデンスに基づき、患者固有の状態に適応できるものにしています。

なぜ脂肪肝治療の需要は人口統計や地域を問わず高まっているのか？

メタボリック症候群の世界の増加や、脂肪肝疾患が静かだが深刻な健康上の脅威であるという認識の高まりに後押しされ、効果的な脂肪肝治療に対する需要はあらゆる年齢層や地域で増加しています。かつては主に高齢者やアルコール乱用歴のある人が罹患する疾患と考えられていたが、現在では小児肥満や座りがちなライフスタイルの増加などにより、小児や青少年を含む若年層でも脂肪肝と診断されるようになっています。米国、ドイツ、日本、英国などの高所得国では、加工食品の消費と糖尿病の有病率が高く、NAFLDは慢性肝疾患の主要な原因の一つとなっています。一方、インド、中国、ブラジル、中東諸国などの新興国では、都市化、食生活の変化、ライフスタイルの変化により、NAFLD患者が急速に増加しており、しばしば医療制度の整備を上回っています。このような人口動態の変化は、早期スクリーニング・プロトコルの採用、公衆衛生教育のための資源配分、治療アクセスの拡大など、ヘルスケア提供者に大きなプレッシャーを与えています。さらに、公衆衛生キャンペーン、オンラインプラットフォーム、医師のアドボカシーを通じた認知度の向上により、診断評価や治療介入を求める人が増えています。製薬企業やヘルスケア機関は、このような患者数の増加や地理的な広がりに対応するため、臨床研究、地域パートナーシップ、教育普及活動を強化することで対応しています。このような世界の疾病負担の増加は、治療市場を拡大させるだけでなく、利害関係者間の協力を促し、スケーラブルで持続可能な解決策を開発しています。

世界の脂肪肝治療市場の成長を促進する主な要因は？

脂肪肝治療市場の成長は、臨床的、経済的、技術的、政策的に多面的な要因によって牽引されており、これらは共に、この健康上の課題の高まりに対処する緊急性と複雑性を反映しています。主要な促進要因は、肥満、糖尿病、メタボリックシンドロームなどの生活習慣病の蔓延の深刻化であり、これらはすべて脂肪肝疾患の発症と進行に強く関連しています。NAFLDとアンメットニーズに特化した治療薬がFDAに承認されていないため、アンメットメディカルニーズが膨大なものとなり、医薬品開発と臨床研究への投資が活発化しています。バイオマーカー探索、画像技術、人工知能の進歩により、早期診断、リスク層別化、治療の最適化が可能になり、患者の転帰と医療システムの効率が大幅に向上しています。健康保険プロバイダーや公的医療制度は、未治療の脂肪肝疾患が長期的なコスト負担をもたらすことをますます認識するようになっており、非侵襲的検査や新たな治療法に対する幅広い償還を促しています。規制当局もまた、緊急介入の必要性に駆り立てられて、有望な新薬候補の承認スケジュールを早めています。バイオ製薬企業、学術機関、診断薬企業の戦略的提携は、イノベーションのパイプラインを拡大し、新規治療の市場投入までの時間を短縮しています。さらに、一般市民の意識の向上、患者支援活動、デジタル関与プラットフォームにより、肝臓の健康管理に積極的な役割を果たす個人の力が強まっています。これらの要因が相まって、世界の脂肪肝治療市場は大幅かつ持続的な拡大を遂げ、かつては見過ごされていた疾患が21世紀の医療の主要な焦点へと変貌を遂げつつあります。

セグメント

医薬品（チアゾリジンジオン、ビタミンE、メトホルミン・スタチン、多価不飽和脂肪酸、アンジオテンシン受容体拮抗薬、ペントキシフィリン）;エンドユーザー（病院、クリニック）

調査対象企業の例（注目の合計42社）

  • AbbVie
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Echosens
  • Enanta Pharmaceuticals
  • Genfit
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Inventiva
  • Madrigal Pharmaceuticals
  • Merck & Co.
  • NGM Biopharmaceuticals
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Praxis Precision Medicines
  • Sanofi
  • Viking Therapeutics
  • Zydus Cadila

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35045

Global Fatty Liver Treatment Market to Reach US$23.1 Billion by 2030

The global market for Fatty Liver Treatment estimated at US$18.7 Billion in the year 2024, is expected to reach US$23.1 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Thiazolidinedione, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Vitamin E segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 6.5% CAGR

The Fatty Liver Treatment market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Fatty Liver Treatment Market - Key Trends & Drivers Summarized

Why Is Fatty Liver Disease Becoming a Major Global Health Concern Necessitating Targeted Treatments?

Fatty liver disease, encompassing both non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), has emerged as a critical public health issue worldwide due to its rising prevalence, close association with metabolic disorders, and potential to progress into more severe hepatic conditions such as steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Modern sedentary lifestyles, poor dietary habits, rising obesity rates, and increased incidence of type 2 diabetes have all contributed to an alarming increase in fatty liver diagnoses, particularly NAFLD, which now affects up to 25% of the global population. Despite its prevalence, fatty liver disease often remains undiagnosed in its early stages due to the lack of symptoms, allowing progression without intervention. As a result, there is growing urgency to develop and implement effective treatment options, ranging from lifestyle modification programs and pharmacologic interventions to surgical solutions in severe cases. Moreover, the potential link between fatty liver disease and cardiovascular complications further elevates its medical significance, making its treatment not only essential for liver health but also for reducing broader systemic risks. As awareness improves among both clinicians and patients, early diagnosis and tailored treatment strategies are becoming crucial in slowing disease progression and reducing long-term healthcare burdens associated with chronic liver diseases.

How Are Therapeutic Innovations Transforming the Management of Fatty Liver Disease?

Advances in medical research and pharmaceutical development are rapidly transforming the landscape of fatty liver treatment, offering hope for more effective disease management and long-term outcomes. Traditionally, lifestyle modifications-such as dietary changes, increased physical activity, and weight loss-have served as the first line of defense against fatty liver disease. However, the limitations of patient adherence and the lack of consistent outcomes have accelerated the pursuit of pharmacologic solutions. Several drug candidates targeting key mechanisms in lipid metabolism, inflammation, fibrosis, and insulin resistance are currently in clinical trials, including FXR agonists, PPAR agonists, and GLP-1 receptor agonists. Drugs like pioglitazone and vitamin E have shown modest success in certain patient subgroups, while newer agents such as obeticholic acid and resmetirom are demonstrating promising results in reducing liver fat content and fibrosis in NASH (non-alcoholic steatohepatitis) patients. In addition to monotherapies, combination therapies that simultaneously address multiple pathogenic pathways are gaining traction as potentially more effective interventions. The integration of non-invasive diagnostic tools such as FibroScan, MRI-PDFF, and serum biomarkers is also enhancing treatment monitoring and enabling personalized care plans. Moreover, digital health tools and mobile health apps are helping patients maintain lifestyle changes through behavior tracking and telemedicine support. These therapeutic innovations are not only improving clinical outcomes but are also making fatty liver treatment more accessible, evidence-based, and adaptable to patient-specific conditions.

Why Is Demand for Fatty Liver Treatments Growing Across Demographics and Geographies?

The demand for effective fatty liver treatments is increasing across all age groups and regions, fueled by the global rise of metabolic syndromes and the growing recognition of fatty liver disease as a silent but serious health threat. While once considered a condition affecting primarily older adults or individuals with a history of alcohol misuse, fatty liver disease is now being diagnosed in younger populations-including children and adolescents-largely due to increasing rates of childhood obesity and sedentary lifestyles. In high-income countries like the U.S., Germany, Japan, and the U.K., where processed food consumption and diabetes prevalence are high, NAFLD has become one of the leading causes of chronic liver disease. Meanwhile, emerging economies such as India, China, Brazil, and countries in the Middle East are witnessing a rapid surge in cases due to urbanization, dietary shifts, and lifestyle transitions-often outpacing healthcare system preparedness. These demographic shifts are creating immense pressure on healthcare providers to adopt early screening protocols, allocate resources for public health education, and expand treatment access. Additionally, rising awareness through public health campaigns, online platforms, and physician advocacy is prompting more individuals to seek diagnostic evaluations and therapeutic interventions. Pharmaceutical companies and healthcare institutions are responding by ramping up clinical research, regional partnerships, and educational outreach to address this growing and geographically widespread patient population. This global rise in disease burden is not only expanding the treatment market but also encouraging collaboration across stakeholders to develop scalable and sustainable solutions.

What Are the Primary Drivers Fueling the Growth of the Fatty Liver Treatment Market Worldwide?

The growth of the fatty liver treatment market is being driven by a multifaceted set of clinical, economic, technological, and policy-related factors that together reflect the urgency and complexity of managing this rising health challenge. A key driver is the escalating prevalence of lifestyle-related diseases such as obesity, diabetes, and metabolic syndrome, all of which are strongly linked to the onset and progression of fatty liver disease. The lack of FDA-approved therapies specifically for NAFLD and NASH has created a massive unmet medical need, fueling robust investment in drug development and clinical research. Advances in biomarker discovery, imaging technologies, and artificial intelligence are enabling earlier diagnosis, risk stratification, and treatment optimization, significantly enhancing patient outcomes and health system efficiency. Health insurance providers and public healthcare systems are increasingly recognizing the long-term cost burden of untreated fatty liver disease, prompting broader reimbursement for non-invasive testing and emerging therapies. Regulatory agencies are also accelerating approval timelines for promising drug candidates, spurred by the urgent need for intervention. Strategic collaborations between biopharmaceutical firms, academic institutions, and diagnostic companies are expanding the innovation pipeline and reducing time-to-market for novel treatments. Furthermore, increased public awareness, patient advocacy efforts, and digital engagement platforms are empowering individuals to take a proactive role in liver health management. Combined, these factors are setting the stage for significant and sustained expansion of the global fatty liver treatment market, transforming a once-overlooked condition into a major focus of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Fatty Liver Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers, Pentoxifylline); End-Use (Hospitals, Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Echosens
  • Enanta Pharmaceuticals
  • Genfit
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Inventiva
  • Madrigal Pharmaceuticals
  • Merck & Co.
  • NGM Biopharmaceuticals
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Praxis Precision Medicines
  • Sanofi
  • Viking Therapeutics
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Fatty Liver Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of NAFLD and NASH Throws the Spotlight on Fatty Liver Drug Development
    • Obesity and Diabetes Epidemic Propels Growth in Demand for Metabolic and Hepatic Therapies
    • Absence of FDA-Approved NASH Drugs Expands Addressable Market for Novel Therapeutics
    • Focus on Fibrosis Prevention and Reversal Strengthens the Business Case for Anti-Fibrotic Agents
    • Push Toward Combination Therapy Approaches Accelerates Innovation in Multi-Target Drug Pipelines
    • Advancements in Non-Invasive Diagnostic Tools Support Early Intervention and Treatment Expansion
    • Patient Stratification and Biomarker Development Enhance Precision in Therapeutic Targeting
    • Lifestyle and Behavioral Health Integration Spurs Demand for Complementary Digital Health Solutions
    • High Prevalence in Aging Population Sustains Growth in Demand for Long-Term Liver Health Management
    • Expanding Role of Genomic and Epigenetic Research Drives Innovation in Mechanism-Based Drug Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fatty Liver Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fatty Liver Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Thiazolidinedione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Thiazolidinedione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Thiazolidinedione by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vitamin E by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vitamin E by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vitamin E by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metformin Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metformin Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metformin Statins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polyunsaturated Fatty Acids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polyunsaturated Fatty Acids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Polyunsaturated Fatty Acids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Angiotensin Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pentoxifylline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pentoxifylline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pentoxifylline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • JAPAN
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CHINA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • EUROPE
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Fatty Liver Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • FRANCE
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • GERMANY
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Fatty Liver Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • INDIA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Fatty Liver Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Fatty Liver Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AFRICA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030

IV. COMPETITION